It has been shown that NRTUA treatment can elicit the expression of circulating pancreatic tumor-specific IgG in Pan02 tumor-bearing mice, and CD4+ T cells play a critical role in the re-challenge of Pan02 tumor (Sanders et al., 2016). This evidence concerns the gene CD4 and neoplasm.